(2R,3R,4S,5S)-2-[6-(2-bicyclo[2.2.1]heptanylamino)purin-9-yl]-5-(1-hydroxy-2-methylprop-1-enyl)oxolane-3,4-diol

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: (2R,3R,4S,5S)-2-[6-(2-bicyclo[2.2.1]heptanylamino)purin-9-yl]-5-(1-hydroxy-2-methylprop-1-enyl)oxolane-3,4-diol
• 化学式: C₂₀H₂₇N₅O₄
• 分子量: 401.5
• InChiKey: BHGZYXAVEAIYDE-WDCAZGPGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• [EN] METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION<br/>[FR] PROCÉDÉS DE PRÉVENTION, DE RÉDUCTION OU DE TRAITEMENT DE LA DÉGÉNÉRESCENCE MACULAIRE
  申请人：INOTEK PHARMACEUTICALS CORP

  公开号：WO2016090005A1

  公开（公告）日：2016-06-09

  The present invention is directed to selective adenosine A1 agonist compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, reduce or prevent age-related macular degeneration.

  本发明涉及选择性腺苷A1激动剂化合物，包括这种化合物的药物组合物，以及使用这种化合物来治疗、减少或预防年龄相关性黄斑变性的方法。
• A METHOD OF PROVIDING OCULAR NEUROPROTECTION
  申请人：Inotek Pharmaceuticals Corporation

  公开号：EP2968388A1

  公开（公告）日：2016-01-20
• METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION
  申请人：Inotek Pharmaceuticals Corporation

  公开号：EP3247715A1

  公开（公告）日：2017-11-29
• [EN] A METHOD OF PROVIDING OCULAR NEUROPROTECTION<br/>[FR] PROCÉDÉ PERMETTANT DE FOURNIR UNE NEUROPROTECTION OCULAIRE
  申请人：INOTEK PHARMACEUTICALS CORP

  公开号：WO2014152733A1

  公开（公告）日：2014-09-25

  Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for preventing, reducing or treating retinal ganglion cell damage comprising administering an effective amount of a purine derivative to a subject in need thereof.